




Testing Taskforce: New California COVID-19 cases, hospitalizations and deaths



Average test positivity past 7 days 6.4%, up 0.6% from last week

Cases have risen slightly over the last two weeks, but remain at relatively low levels

14 day average hospitalizations have plateaued but are still 1.5x the low in October

7 day average deaths remain at low levels.

- **Turnaround Time (for the week starting 02/12)**
- **92%** of PCR tests TAT < 1 day (1% decrease from the previous week)
- **98%** of tests TAT < 2 days (no change from the previous week)
- *as of 02/21 -- Source: CalREDIE*

Feb 16 2023 with data as of Feb 14, 2023.


<https://covid19.ca.gov/state-dashboard/>

FDA EUA Process and Federal Public Health Emergency

- **Q2: Once the public health emergency is over, what becomes of medical products (such as drugs, tests, vaccines) that have an EUA?**
- **A:** As noted above, An EUA declaration is distinct from, and not dependent on, an HHS PHE declaration under section 319 of the PHS Act, and, therefore, an EUA may remain in effect beyond the duration of the section 319 PHE declaration if all other statutory conditions are met.
- FDA recognizes that it will take time for manufacturers, health care facilities, providers, patients, and other stakeholders to transition away from EUA products and the policies that support them. As we have recognized during the entire COVID-19 response, continued flexibility will be appropriate—while maintaining necessary oversight within our regulatory authorities under applicable laws—to support stakeholders during such transitions, while maintaining our high standards to protect consumers.
- <https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/faqs-what-happens-euas-when-public-health-emergency-ends>

Daily new confirmed COVID-19 cases per million people

7-day rolling average. Due to limited testing, the number of confirmed cases is lower than the true number of infections.




COVID-19 cases are falling in many countries around the world. In Japan, Hong Kong they are falling from a large peak. In the US cases are staying steady and relatively low. In Europe, cases remain at low levels except for in Austria where there was a rise in cases.

Daily new confirmed COVID-19 deaths per million people




7-day rolling average. Due to varying protocols and challenges in the attribution of the cause of death, the number of confirmed deaths may not accurately represent the true number of deaths caused by COVID-19.

LINEAR LOG



Variant Update: CDC Nowcast Estimate





USA

WHO label	Lineage #	US Class	%Total	
Omicron	XBB.1.5	VOC	80.2%	74.
	BQ.1.1	VOC	12.1%	9.1
	BQ.1	VOC	3.7%	2.7
	XBB	VOC	1.5%	1.2
	CH.1.1	VOC	1.2%	0.9
	BN.1	VOC	0.5%	0.4
	BA.5	VOC	0.2%	0.1
	BF.7	VOC	0.2%	0.1
	BA.5.2.6	VOC	0.1%	0.1
	BA.2	VOC	0.1%	0.0
	BF.11	VOC	0.0%	0.0
	BA.2.75	VOC	0.0%	0.0
	BA.2.75.2	VOC	0.0%	0.0
	BA.4.6	VOC	0.0%	0.0
	B.1.1.529	VOC	0.0%	0.0
	BA.2.12.1	VOC	0.0%	0.0
BA.1.1	VOC	0.0%	0.0	
Delta	B.1.617.2	VBM	0.0%	0.0
Other	Other*		0.1%	0.0

XBB.1.5

- Fusion of BA.2.10.1.1 and BA.2.75.3.1.1.1
- Immune evasive, evades monoclonal antibodies
- Paxlovid still works
- Lineage has the greatest increase in growth in the US
- Highest number of cases in New York and East Coast 96.9% vs 70.4% for California
- Not seeing a rise in hospitalizations or cases with increasing XBB.1.5 prevalence



Paxlovid Resistance Currently Not Seen

- Currently we are **NOT** seeing signs of mutations in SARS-CoV-2 likely to impact the effectiveness of Paxlovid
- We are monitoring the genomic sequencing data for known Paxlovid resistance mutations

Figure 1. Percentage of Influenza Detections at Clinical Sentinel Laboratories, 2017–2023 Season to Date




Figure 13. Percentage of RSV Detections at Clinical Sentinel Laboratories, 2017–2023 Season to Date

